Vascular symptoms in patients with primary Raynaud's phenomenon are not exacerbated by propranolol or labetalol.
D000328:Adult; D000368:Aged; D001794:Blood Pressure / Q000187:drug effects; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004983:Ethanolamines / Q000009:adverse effects*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D007741:Labetalol / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000009:adverse effects* / Q000627:therapeutic use; D011928:Raynaud Disease / Q000150:complications / Q000503:physiopathology*; D012881:Skin Temperature / Q000187:drug effects
D004983:Ethanolamines; D011433:Propranolol; D007741:Labetalol